Aurobindo's US Arm Launches ADQUEY Ointment, Marking Its Entry Into the Dermatology Market

Aurobindo Pharma Limited said its biopharmaceutical subsidiary Acrotech Biopharma Inc. has announced the US launch of ADQUEY, a difamilast 1 percent ointment. ADQUEY is a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and older, and the launch marks Acrotech's entry into the US dermatology market.

Click Here – Get Free Investment Predictions

The announcement did not include pricing, projected revenue contribution or launch volume figures. This article covers what the product addresses, the stock's current levels, and the risks for investors.

What ADQUEY Is and What It Means for Aurobindo

Item	Detail
Launching entity	Acrotech Biopharma Inc. (Aurobindo Pharma subsidiary)
Product	ADQUEY (difamilast 1%) ointment
Indication	Mild-to-moderate atopic dermatitis
Eligible patients	Adults and pediatric patients aged 2 years and older
Classification	Non-steroidal topical treatment
Significance	Marks Acrotech's entry into the US dermatology market

Acrotech Biopharma has historically focused on oncology and hematology products, so a dermatology launch represents a diversification of its therapeutic focus within the US market. Non-steroidal topical treatments for atopic dermatitis are a growing category, as patients and physicians often seek alternatives to long-term steroid-based creams for chronic skin conditions.

Also read – Stocks to Watch Today: Alicon Castalloy Jumps 20%, Ircon and Rites Surge on Heavy Volume

Aurobindo Pharma Share Price Today: Numbers and Technical Levels

Metric	Value (1 Oct, 9:13 AM)
Aurobindo Pharma share price	Rs 1,677.90 (up 0.35%)
Previous close	Rs 1,672.00
52-week high / low	Rs 1,740.00 / Rs 1,066.80
RSI (14-day)	51.9
SuperTrend	Bullish, support at Rs 1,607.04
20-day average	Rs 1,686.23
Market cap	Rs 95,887 crore
P/E vs industry P/E	25.84 vs 38.34
Return on equity	9.25%

The Aurobindo Pharma share price is just 3.6 percent below its 52-week high of Rs 1,740, trading close to its 20-day average of Rs 1,686.23 with a neutral RSI of 51.9. The SuperTrend indicator remains bullish with support at Rs 1,607.04.

Compare Pharma Stocks and Live Levels on the Univest Screener

Valuation Behind the Aurobindo Pharma Share Price

Aurobindo Pharma trades at a P/E of 25.84 against a pharmaceutical industry average of 38.34, a discount that reflects the company's revenue base, which is still largely weighted toward generic drugs rather than the specialty and branded products that typically command higher multiples. Return on equity of 9.25 percent and debt to equity of 0.21 are moderate.

Risks for the Aurobindo Pharma Share Price

New product launches like ADQUEY typically take time to build meaningful revenue, so the near-term financial impact on Aurobindo's consolidated results is likely to be limited. Competitive intensity in the US dermatology and topical treatment market, where several established players already operate, is a factor for Acrotech's new entry. US regulatory and pricing risk for pharmaceutical products generally, including scrutiny of drug pricing, remains a structural consideration for the sector.

Download the Univest iOS App or Univest Android App to track the Aurobindo Pharma share price and get alerts on new product launches.

Conclusion

The Aurobindo Pharma share price edged higher after US subsidiary Acrotech Biopharma launched ADQUEY ointment, marking its entry into the dermatology market, though the near-term financial contribution is likely to be limited. A valuation discount to the pharma industry average and a bullish technical trend are supports, while competitive intensity in US dermatology and typical new-launch ramp-up time are the considerations. Investors deciding whether to buy Aurobindo Pharma shares should watch the Rs 1,686.23 average as resistance, follow stop-loss levels and consult a SEBI-registered adviser.

Frequently Asked Questions

What is the Aurobindo Pharma share price today?

Ans. The Aurobindo Pharma share price was Rs 1,677.90 at 9:13 AM on 1 October 2026, up 0.35 percent from Rs 1,672.

What product has Aurobindo's subsidiary launched?

Ans. Acrotech Biopharma launched ADQUEY, a difamilast 1 percent ointment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two and older.

What is Acrotech Biopharma's usual therapeutic focus?

Ans. It has historically focused on oncology and hematology products, so this dermatology launch is a diversification into a new therapeutic area.

Is ADQUEY a steroid-based treatment?

Ans. No. It is described as a non-steroidal topical treatment for atopic dermatitis.

Is the Aurobindo Pharma share price expensive?

Ans. The P/E of 25.84 is below the pharmaceutical industry average of 38.34, a discount tied to the company's largely generic-drug revenue base.

What are the key technical levels for the Aurobindo Pharma share price?

Ans. The key levels are SuperTrend support at Rs 1,607.04 and the 20-day average of Rs 1,686.23. The RSI is 51.9.

How far is Aurobindo Pharma from its 52-week high?

Ans. The stock is about 3.6 percent below its 52-week high of Rs 1,740.

Should I buy Aurobindo Pharma shares after this launch?

Ans. The launch is a long-term positive for diversification, but near-term revenue impact is likely limited. Use a stop-loss and consult a SEBI-registered adviser.